Subscribe
shutterstock_1743001619_glen_berlin
Glen Berlin / Shutterstock.com
22 June 2023EuropeMarisa Woutersen

UK appoints first female Lord Chief Justice in 755 years

Dame Sue Carr takes over from Lord Burnett of Maldon, assuming responsibilities in October.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Femtech: from taboo to multibillion-dollar industry
7 September 2023   Technology is continuing to transform women’s healthcare and female inventors are driving the change—but more needs to be done to ensure they secure IP rights.
Biotechnology
Genentech refused appeal in Herceptin case
27 May 2014   Justice Colin Birss has refused Roche’s biotechnology subsidiary Genentech the permission to appeal against an English High Court decision in which two patents covering its blockbuster breast cancer drug, Herceptin (trastuzumab), were revoked.
Big Pharma
LSIPR 50 2017: Mr Justice Richard Arnold
10 November 2017   Mr Justice Richard Arnold was selected in the LSIPR 50 2017 publication for​ ​his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Biotechnology
Femtech: from taboo to multibillion-dollar industry
7 September 2023   Technology is continuing to transform women’s healthcare and female inventors are driving the change—but more needs to be done to ensure they secure IP rights.
Biotechnology
Genentech refused appeal in Herceptin case
27 May 2014   Justice Colin Birss has refused Roche’s biotechnology subsidiary Genentech the permission to appeal against an English High Court decision in which two patents covering its blockbuster breast cancer drug, Herceptin (trastuzumab), were revoked.
Big Pharma
LSIPR 50 2017: Mr Justice Richard Arnold
10 November 2017   Mr Justice Richard Arnold was selected in the LSIPR 50 2017 publication for​ ​his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.

More on this story

Biotechnology
Femtech: from taboo to multibillion-dollar industry
7 September 2023   Technology is continuing to transform women’s healthcare and female inventors are driving the change—but more needs to be done to ensure they secure IP rights.
Biotechnology
Genentech refused appeal in Herceptin case
27 May 2014   Justice Colin Birss has refused Roche’s biotechnology subsidiary Genentech the permission to appeal against an English High Court decision in which two patents covering its blockbuster breast cancer drug, Herceptin (trastuzumab), were revoked.
Big Pharma
LSIPR 50 2017: Mr Justice Richard Arnold
10 November 2017   Mr Justice Richard Arnold was selected in the LSIPR 50 2017 publication for​ ​his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott